Continuing to gain momentum as a novel treatment strategy, targeted radiotherapy relies on and exploits the characteristics of malignant cells to attack tumors with radiation. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this exciting radiopharmaceutical field with up-to-date developments and step-by-step discussion covering a range of diverse topics, including optimization in the design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from pivotal clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. Unique aspects of the book include:

• A translational focus on development, preclinical, and clinical evaluation of novel targeted radiopharmaceuticals for treating cancer

• A discussion on health economics issues that have an impact on the ultimate use of targeted radiotherapy in clinical oncology

• A broad discussion of the utility of targeted radiotherapy for multiple tumor types

• New and emerging areas like molecular imaging, the bystander effect, and combining targeted radiotherapy with cytolytic virus therapy of tumors

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer enlists internationally renowned experts and emerging leaders in the field who explain the groundbreaking science that has delivered a wealth of new findings and is defining the role of this new cancer treatment in the future. Review of the current state of the art provides provocative insight from today's cancer researchers as they reach for tomorrow's cures.